Clinical trials: Chronic Obstructive Pulmonary
Chronic Obstructive Pulmonary Disease
Factors Determining Quality of Life Related to Respiratory Status According to Gender of Chronic Obstructive Pulmonary Disease (COPD) Patients
The purpose of this study is to evaluate with sufficient precision and according to gender the determining independent factors of quality of life related to respiratory status of patient with moderate to severe COPD.
- Trial name
- VITALITE (NCT01007734)
- Where
- 178 sites in France
- Volunteers
- 449 people
- Sponsor
- AstraZeneca
COPD
Portable Oxygen Concentrator to Improve Quality of Life in Chronic Obstructive Pulmonary Disease
Evaluate subjects in an prospective observational study Subjects will be administered scientifically validated questionnaires Determine the affect of the Portable Oxygen Concentrator (POC) on improvements in: 1.
- Trial name
- NCT01948544
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- StratiHealth
Chronic Obstructive Pulmonary Disease
Flutiform® Compared With Seretide® in the Treatment of COPD
The purpose of this study is to investigate whether flutiform® is effective and safe in the treatment of chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT02195375
- Testing
- Flutiform 500/20 µg BID, Flutiform 250/10 µg BID, Seretide Accuhaler 50/500 µg BID
- Where
- 5 sites in Australia, China and 3 more
- Volunteers
- 923 people
- Sponsor
- Mundipharma Research Limited
Pulmonary Emphysema
Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE)
The purpose of this study is to demonstrate the safety and efficacy of AeriSeal System treatment plus optimal medical therapy compared in patients with advanced upper lobe predominant (ULP) heterogeneous emphysema.
- Trial name
- ASPIRE (NCT01449292)
- Testing
- Treatment plus Optimal Medical Therapy, Optimal Medical Therapy
- Where
- 40 sites in United States, France and 5 more
- Volunteers
- 300 people
- Sponsor
- Aeris Therapeutics
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting
A significant proportion of COPD subjects experience muscle wasting, which has been associated with increased morbidity, impaired physical functioning, and a poor quality of life.
- Trial name
- NCT01388920
- Testing
- Tesamorelin
- Volunteers
- 3 people
- Sponsor
- Theratechnologies
Pulmonary Disease, Chronic Obstructive
Respiration Rate Monitoring in COPD Patients
Assess the feasibility of using remote respiration rate monitoring as a component of home care, how respiration rate data may be used in combination with other data to potentially improve response to symptoms, and to generate…
- Trial name
- NCT03030313
- Testing
- Reassure Non-Contact Respiration Monitor
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- ResMed
Pulmonary Disease, Chronic Obstructive
Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Pulmonary Disease
New perceptions about handling and patient satisfaction of the everyday use of Berodual® Respimat® in patients with chronic obstructive lung disease (COLD).
- Trial name
- NCT02231320
- Testing
- Berodual® Respimat® - inhaler
- Volunteers
- 236 people
- Sponsor
- Boehringer Ingelheim
Foot Ulcer, Diabetic
Study to Assess the Safety of DERMASEAL for Diabetic Foot Ulcers
The goal of this clinical trial is to determine the safety of DERMASEAL for the treatment of non-healing, neuropathic diabetic foot ulcers. The main outcome measure is safety.
- Trial name
- NCT05586542
- Testing
- DERMASEAL, Plasma Film, Standard of Care
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Vitruvian Medical Devices, Inc.
Chronic Lymphocytic Leukemia
Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia
The treatment combination of Rituxan® (rituximab) and fludarabine has previously been reported to produce a high percentage of responses with less toxicity than other combination treatments.
- Trial name
- NCT00078234
- Testing
- Oblimersen-rituximab-fludarabine
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Genta Incorporated
Pulmonary Emphysema
Post Market Registry Study of the AeriSeal System
Obtain and analyze medical record data on patients with advanced emphysema who receive treatment with the AeriSeal System to better understand safety and effectiveness in the post-market setting; Provide participating physicians…
- Trial name
- NCT01520064
- Where
- 12 sites in Germany, Israel
- Volunteers
- 25 people
- Sponsor
- Aeris Therapeutics
Chronic Obstructive Pulmonary Disease, Alpha1-antitrypsin Deficiency
ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study
The purpose of this study is to evaluate the efficacy of ARALAST NP A1PI augmentation therapy 120 milligrams per kilogram (mg/kg) body weight (BW)/week compared with an external placebo comparator on the loss of emphysematous…
- Trial name
- NCT04440488
- Testing
- ARALAST NP
- Sponsor
- Shire
Pulmonary Disease, Chronic Obstructive
A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects
GW642444 and GSK233705 are in development for treatment of Chronic Obstructive Pulmonary Disease. Development of these two inhaled drugs as a combination therapy would have potential for improved patient benefit as they both work…
- Trial name
- NCT00783003
- Testing
- GSK233705 and GW642444, GW642444, GSK233705
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
GSK961081 Alone and With Fluticasone Furoate (FF), Phase 1 (Ph1), Single Dose Regimen (SD), Repeat Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV)
Batefenterol (BAT) is a novel bifunctional molecule that combines muscarinic antagonism and beta2-agonism in a single molecule and is in development for the treatment of chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT02666287
- Testing
- BAT/FF, BAT, FF
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Formoterol-HFA 3-month Study in Chronic Obstructive Pulmonary Disease (COPD) Patients
The purpose of this study is to demonstrate the clinical equivalence of formoterol-HFA pMDI 12µg/actuation administered twice daily to formoterol DPI 12µg/capsule delivered by the Aerolizer inhaler and administered twice daily in…
- Trial name
- NCT00972140
- Testing
- Formoterol
- Where
- Poland
- Volunteers
- 457 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
COPD
Real-World Treatment Patterns and Patient Reported Outcome in COPD (REMIND)
This retrospective observational study aims to report distribution of the proportion of symptomatic Chronic obstructive pulmonary disease (COPD) patients classified by the COPD Assessment Test (CAT) managed with single or dual…
- Trial name
- REMIND (NCT05903989)
- Where
- Japan
- Volunteers
- 708 people
- Sponsor
- AstraZeneca
Asthma, Mastocytosis
Mast Cell Activation Test in Allergic Disease
Activation of mast cells in the immune system is known to cause allergic reactions sometimes with severe systemic symptoms. The investigators have recently developed a blood-based mast cell activation diagnostic test in which…
- Conditions
- Asthma, Mastocytosis, Mast Cell Activation Syndrome, Food Allergy
- Trial name
- NCT03406325
- Where
- Hong Kong
- Volunteers
- 19 people
- Sponsor
- Hong Kong Sanatorium & Hospital
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD
Randomized,double-blind,multicenter,multinational,parallel-group,Phase III study to demonstrate the superiority of the triple fixed combination of beclometasone + formoterol + glycopyrrolate (BDP/FF/GB) administered via…
- Trial name
- TRILOGY (NCT01917331)
- Testing
- Beclometasone/Formoterol/Glycopyrrolate, Beclometasone/Formoterol
- Where
- Hungary
- Volunteers
- 1,368 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Diabetes, Diabetes Mellitus, Type 1
Safety of Inhaled Human Insulin in Subjects With Diabetes Mellitus and Chronic Obstructive Pulmonary Disease (COPD)
This trial is conducted in Europe, Asia and South America. A one-year clinical trial to compare the safety of inhaled human insulin to subcutaneous insulin aspart in subjects with type 1 or type 2 diabetes and chronic obstructive…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Chronic Obstructive Pulmonary Disease
- Trial name
- iINHALE 8 (NCT00472953)
- Testing
- inhaled human insulin, insulin aspart
- Where
- 27 sites in Argentina, India and 5 more
- Volunteers
- 38 people
- Sponsor
- Novo Nordisk A/S
Chronic Obstructive Pulmonary Disease
Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.
This study is designed to assess the effect of QVA149 (110/50 ug q.d.) versus placebo on pulmonary function and average physical activity levels in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- MOVE (NCT01996319)
- Testing
- QVA149
- Where
- 30 sites in Germany
- Volunteers
- 194 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
Study to assess the efficacy and safety of four doses of budesonide inhalation aerosol (BD MDI, PT008) relative to placebo MDI in adult subjects with mild to moderate persistent asthma.
- Trial name
- NCT02105012
- Testing
- BD MDI 320 µg, BD MDI 160 µg, BD MDI 80 µg
- Where
- 41 sites in United States
- Volunteers
- 147 people
- Sponsor
- Pearl Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.